Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
The inspection was successfully completed
The Alathur facility specializes in the production of Cephalosporin antibiotics
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
Branded formulation business continues to perform well across domestic and export markets
Consolidated manufacturing volumes for Q3 FY25 remained stable at 132,187 KL, while for 9M FY25 it stood at 372,505 KL
International Meeting of World Pharmacopoeias serves as a vital platform to foster international collaboration in pharmacopoeial science and regulatory harmonization
Subscribe To Our Newsletter & Stay Updated